Max Healthcare board meet Feb 5, 2026 for Q3FY26

Max Healthcare Institute has informed the stock exchanges that its Board of Directors will meet on February 5, 2026, to consider and approve the company’s unaudited financial results. The agenda covers both standalone and consolidated results for the quarter and nine months ended December 31, 2025. Such board meeting intimations are a key part of listed-company disclosures because they set the timetable for earnings visibility for investors. The company said it has communicated the schedule to both the National Stock Exchange of India and BSE, in line with the SEBI (Listing Obligations and Disclosure Requirements) framework. The update also reiterates trading window restrictions for designated persons until after the results are declared. For market participants tracking the stock closely, the timing matters because it anchors when formal numbers will be published.

What the company disclosed to NSE and BSE

Max Healthcare Institute said the meeting is scheduled for Thursday, February 5, 2026. The company’s stated purpose is to consider and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, and for the nine months ended December 31, 2025. The filing was made as an advance intimation under Regulation 29 of SEBI (LODR) Regulations, 2015. The company also indicated that the disclosure would be made available on its official website (www.maxhealthcare.in). In the exchange communication cited, Max Healthcare’s NSE symbol is MAXHEALTH and the BSE scrip code is 543220. The intimation was signed by Dhiraj Aroraa, SVP - Company Secretary and Compliance Officer, and dated January 28, 2026.

Board meeting agenda and reporting periods

The board meeting is tied to two reporting windows: the quarter ended December 31, 2025, and the nine months ended December 31, 2025. The company specified that the results to be considered are unaudited and will be presented for both standalone and consolidated accounts. This distinction matters for stakeholders because consolidated results reflect performance across the broader group, while standalone focuses on the listed entity. The disclosure sets expectations for the formal approval process, which typically precedes stock exchange submission of financial statements. It also provides clarity that the board meeting is primarily results-focused rather than linked to a separate corporate action.

Trading window closure and who it applies to

Alongside the board meeting intimation, Max Healthcare Institute reiterated trading restrictions in line with compliance requirements. The trading window closure applies to all designated persons and their immediate relatives. The company said the closure will remain in force until 48 hours after the declaration of financial results. It also referenced an earlier intimation dated December 29, 2025, from which the restriction continues. Trading window closures are designed to reduce the risk of trading on unpublished price-sensitive information during the results preparation and approval cycle.

Disclosures linked to the results cycle

The material shared also references several results-related disclosures around this period. These include a schedule of earnings call for investors and analysts, a presentation on earnings update for the quarter and nine months ended December 31, 2025, and a newspaper publication pertaining to the same financial results period. A transcript of the earnings call held on February 6, 2026 is also listed as an announcement under Regulation 30 (LODR). Together, these items form the broader disclosure set that typically accompanies results, offering investors management commentary and supporting documents beyond the headline numbers.

Recent and upcoming board meeting dates

Exchange data in the provided material lists recent board meetings and their stated purposes. The most immediate sequence includes November 14, 2025 (Quarterly Results), August 13, 2025 (Quarterly Results), and May 20, 2025 (Audited Results and Final Dividend). The record also shows older results meetings across 2024 and 2023, and a February 2, 2023 meeting that included consideration of a proposal for issuance of non-convertible debentures. Separately, corporate actions information includes a board meeting entry dated April 8, 2026 with agenda stated as Audited Result. These dates help investors understand the cadence of periodic reporting and governance events.

Block trade on NSE worth ₹64.66 crore

Max Healthcare Institute also saw notable institutional activity in January 2026. The material states the company executed a block trade on NSE valued at ₹64.66 crore, involving 645,871 shares at an execution price of ₹1,001.10 per share. Block trades are typically associated with large, negotiated transactions between institutional participants. While the disclosure does not specify buyer or seller identities, it confirms the size, price, and exchange venue. For investors, such activity is often tracked as a liquidity and positioning indicator, especially when it coincides with an earnings window.

Stock snapshot: price context, 52-week range, and returns

The content includes market metrics and historical return snapshots. The 52-week range is shown as ₹933.80 to ₹1,314.30, and one screen indicates the stock trading near the 52-week high of ₹1,314.30. A return table lists: 1 day -0.83%, 5 days +0.88%, 1 month +5.87%, 6 months -8.54%, 1 year -12.98%, and 5 years +351.59%. Another price line shows ₹1,009.30 with a -0.83% move for the day in that snapshot. These figures provide context on near-term movement versus longer-term performance, without implying a forward view.

FY25 dividend and financial highlights disclosed in filings

The material also includes extracts from the company’s reporting and corporate action information around FY 2024-25. The board recommended a final dividend of ₹1.50 per equity share of face value ₹10 for FY 2024-25, subject to shareholder approval at the AGM. The record date for the final dividend was fixed as Friday, July 4, 2025, and the dividend was to be paid or dispatched within 30 days from the conclusion of the AGM if approved. The company also stated that it amended its Dividend Distribution Policy on May 20, 2025, with a guiding principle that the board may declare dividend up to a payout ratio of 40% of profits after tax, while endeavouring to recommend a minimum dividend of 10% of face value each year.

From the financial highlight extract presented in lakh terms, FY 2024-25 total income is stated as ₹1,03,326 lakh, which is ₹1,033.26 crore after unit normalisation. Profit before tax for FY 2024-25 is stated as ₹1,02,035 lakh, which is ₹1,020.35 crore. Net profit after tax and exceptional items is stated as ₹70,107 lakh (₹701.07 crore) compared with ₹68,726 lakh (₹687.26 crore) for FY 2023-24. On a like-to-like basis excluding an exceptional item of ₹7,363 lakh (₹73.63 crore), the FY 2024-25 net profit after tax is stated as ₹77,470 lakh (₹774.70 crore).

Key facts table

Why this board meeting matters

For investors, the February 5, 2026 meeting is primarily about the timing of formal numbers for the quarter and nine-month period ended December 31, 2025. Because the company has explicitly flagged approval of both standalone and consolidated unaudited results, the meeting sets the sequence for disclosures that typically include the financial statements, earnings presentation, and follow-up Q&A via the investor call. The continuation of the trading window closure reinforces that the company is treating the period as price-sensitive, consistent with listed-company compliance practice. Alongside this, the January block trade highlights that large transactions have occurred in the stock close to the results cycle, though the filing does not provide participant details. Investors also have prior corporate action context, including the FY25 final dividend recommendation and policy changes referenced in the company’s reporting.

What to track next

The next concrete milestone is the board meeting on February 5, 2026, followed by the release of the unaudited results for the quarter and nine months ended December 31, 2025. The material also references a transcript for an earnings call held on February 6, 2026, indicating that management engagement with analysts and investors is part of the disclosure flow. Separately, corporate actions information includes an April 8, 2026 board meeting agenda listed as Audited Result, which will be another scheduled point for financial updates. Until then, the trading window restrictions remain in place for designated persons as described in the company’s exchange communication.